Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published research on aging biology and protein biomarkers. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, supplement regimen, or any health-related decision.

In a 2010 analysis published by Yamazaki and colleagues, serum Klotho concentrations were measured across 1,011 Japanese adults between ages 25 and 88. The pattern was consistent: circulating Klotho peaked around age 25 and declined steadily across each subsequent decade, with the oldest cohort showing levels approximately 50 to 60 percent lower than the youngest. That magnitude of decline — more than halved by the ninth decade of life — has since been replicated in non-Japanese cohorts and has positioned serum Klotho as one of the more discussed age-associated biomarker candidates in molecular gerontology.

This article covers the serum decline picture, the recent research direction opened by Dena Dubal’s lab at UCSF around VS Klotho protein administration, and the molecular pathway connecting NAD+ and SIRT1 to Klotho gene expression. For the underlying biology — the 1997 Kuro-o discovery at the University of Tokyo, the FGF23 co-receptor mechanism, and the bidirectional mouse aging phenotype evidence — see the Klotho protein and aging discovery overview.

TL;DR

• Serum Klotho in human cohort data shows an age-associated decline of approximately 50–60% between peak (around age 25) and the eighth decade, per Yamazaki et al. 2010 and follow-up analyses
• Japanese geriatric cohort research in adults aged 70–90 finds lower serum Klotho associated with higher arterial stiffness, lower physical function, and lower cognitive scores — observational associations, not established causal relationships
• Research from Dena Dubal’s lab at UCSF, published in Nature in 2021, showed that systemic administration of a VS Klotho protein fragment improved cognitive and muscle function in aged mice — a mouse model finding, not a human clinical result
• Kida and colleagues (2011) reported that SIRT1 — a NAD+-dependent deacetylase — appears to promote Klotho mRNA expression in kidney tubular cells, creating a molecular link between NAD+ availability, sirtuin activity, and Klotho production at the cell biology level
• Calibration: no human RCT on Klotho supplementation exists; serum Klotho lacks validated clinical reference ranges; the NAD+–SIRT1–Klotho pathway is established at cell culture level, not in human aging endpoints

What the serum Klotho decline picture shows

The Yamazaki 2010 cohort data is not the only source confirming age-related decline. The InCHIANTI study of community-dwelling older adults and multi-site American cohort analyses have replicated the directional pattern: lower serum Klotho is consistently found in older age bands. The primary source of circulating soluble Klotho is the kidney’s distal convoluted tubule, and kidney function itself declines with age — which creates an interpretive ambiguity at the center of the biomarker question. Whether Klotho falls because of kidney aging, or Klotho decline independently contributes to the kidney function trajectory and to outcomes in other organs, cannot be separated from cross-sectional cohort data alone.

What Japanese geriatric research has added is a more granular picture in the 70-to-90 age range. Studies from groups at Tohoku University examining community-dwelling older Japanese adults found that lower measured serum Klotho was associated with composite measures of healthy aging — including higher arterial stiffness indices, lower scores on physical performance batteries, and lower cognitive test performance — with associations that persisted after adjustment for standard kidney function markers. These directional findings are consistent with the non-Japanese cohort literature and with the multi-organ effects of the Klotho-FGF23 axis described in molecular biology research. They remain observational: lower serum Klotho in an older population is associated with worse aging outcomes, not established as a driver of those outcomes.

One practical implication of the kidney-Klotho connection: strategies with established evidence for kidney health — blood pressure management, adequate hydration, moderating dietary phosphate excess — address the same biological system where Klotho is produced. This does not amount to a Klotho-specific protocol, but it connects kidney care to the organ system most directly relevant to circulating Klotho levels.

VS Klotho and the Dubal lab direction

The KLOTHO-VS haplotype is a naturally occurring variant in the human Klotho gene. In genetic association analyses, single-copy carriers of the VS variant — roughly 20 to 25 percent of the population in studied cohorts — show higher circulating Klotho and, in Dubal lab research published in 2014, better performance on multiple cognitive tests across independent cohorts independent of APOE genotype.

In 2021, work from Dubal’s lab at UCSF published in Nature extended this into a protein administration direction. The researchers administered a peptide fragment corresponding to the extracellular domain of the VS Klotho variant systemically to aged mice. Animals receiving the fragment showed improvements in spatial memory on water maze testing and in muscle function measures compared with aged control animals. The effect was observed in the study period without apparent adverse effects in the treated group.

The calibration this finding requires is substantial. The experiment was in mouse models, not humans. Klotho protein — whether full-length or a fragment — cannot be administered orally; it is a protein that would be degraded in the gut before reaching circulation in meaningful amounts. Systemic delivery of a protein fragment in a rodent aging model does not directly establish feasibility, safety, or efficacy in humans at any relevant dose or delivery method. No human clinical trial on Klotho protein administration has reported longevity or functional aging outcomes.

The genetic association evidence — that VS carriers show higher Klotho and better cognitive performance in cross-sectional genetic studies — sits on a different layer than the mouse intervention work. Genetic variants affect lifetime development in complex ways, and a carrier study does not establish that acutely raising Klotho in non-carrier older adults produces similar effects. Both findings are biologically interesting and appropriately described as research directions with human translational relevance not yet established at clinical-outcome level.

The NAD+–SIRT1–Klotho molecular connection

A 2011 paper from Kida and colleagues reported that SIRT1 — the NAD+-dependent sirtuin most studied in the caloric restriction and longevity pathway — appears to promote Klotho mRNA expression in kidney tubular cells. When SIRT1 was activated in the experimental conditions examined, Klotho gene transcription in these cells increased; when SIRT1 was inhibited, Klotho expression fell.

This creates a molecular link between two of the more studied areas in aging biology. Sirtuins require NAD+ as a substrate to carry out deacetylation reactions. When NAD+ availability falls — as tissue analyses from animal models and some human data suggest occurs with age — SIRT1 catalytic activity diminishes. If SIRT1 activity supports Klotho expression in the kidney, then the age-associated NAD+ decline may contribute to reduced renal Klotho production and lower circulating soluble Klotho through a discrete molecular mechanism, operating alongside the kidney functional changes that independently reduce Klotho output.

The evidence chain in living humans remains indirect at every step. The Kida 2011 paper and related cell culture work establish a biochemical mechanism. Whether oral NAD+ precursor supplementation (NMN, NR) raises SIRT1 activity in human kidney tubular cells at a level that meaningfully increases Klotho mRNA expression — and whether that expression change produces measurable serum Klotho increases in aging adults — has not been reported in a published human trial. Human NAD+ precursor trials have confirmed that NMN and NR raise blood NAD+ levels; downstream effects on serum Klotho have not been the primary endpoints of those studies. The NAD+ precursor evidence in human trials is reviewed in the NAD+ and aging decline research article.

The pathway — elevated NAD+ → SIRT1 activation → Klotho mRNA induction → higher soluble Klotho → reduced aging-associated organ dysfunction — is biologically coherent and connects to the epigenetic and metabolic aging programs described across the research cluster. It is mechanistic plausibility and cell culture data. The distance between a cell culture mechanism and a confirmed human aging endpoint is where most promising molecular aging pathways currently sit, and the NAD+–SIRT1–Klotho path is not an exception.

What the current evidence does not establish

Serum Klotho testing as clinical guidance. Commercial Klotho tests are available, but no validated clinical reference range exists that would allow interpretation of an individual result as indicating specific health risk or warranting intervention. Assay platform variability across studies has been a documented technical limitation in the field. A low Klotho reading from a direct-to-consumer test does not have a confirmed actionable clinical interpretation at the current evidence stage.

Supplements that raise serum Klotho in humans. No supplement has been shown in an adequately powered human trial to raise serum Klotho at a magnitude associated with health outcomes. Aerobic exercise is the intervention with the most consistent human observational evidence for association with higher serum Klotho in adults over 60, likely through improved renal blood flow and reduced systemic inflammatory tone; this is a physical activity association, not a supplement finding.

Causal direction in observational cohorts. The consistent cross-sectional finding — lower serum Klotho in older adults with worse aging outcomes — does not establish that declining Klotho drives those outcomes. Older adults with lower Klotho may have lower Klotho because of kidney aging processes that also independently drive the outcomes with which it correlates. Separating this requires interventional data not yet available.

Practical framing and further reading

The areas where Klotho biology connects most directly to practical action remain kidney care and aerobic exercise — two domains where conventional health guidance already points, and where the Klotho mechanism adds biological context rather than changing the recommendation.

The molecular research cluster connecting Klotho to NAD+, sirtuins, epigenetic clocks, cellular senescence, and FOXO3 genetics gives the protein an integrative position in aging biology that is scientifically coherent. Each connection is at the cell biology or animal model evidence stage for its most specific claims; the population-level aging correlates in observational cohorts are the closest current human evidence. For the sirtuins and NAD+ pathway covering SIRT1’s broader role in caloric restriction and longevity, see the sirtuins and NAD+ research article. The FOXO3 genetic evidence and Okinawan centenarian cohort context are covered in the FOXO3 longevity gene piece. Cellular senescence mechanisms connecting to the Klotho biology picture are in the senolytics and cellular senescence article.

For the primary literature: the Yamazaki et al. 2010 paper on serum Klotho across human aging is available through PubMed. The 2021 Dubal lab Nature paper on VS Klotho fragment in aged mice represents the current frontier in Klotho protein administration research. Kida et al. 2011 covers the SIRT1–Klotho gene expression link in kidney cells.

David Sinclair’s Lifespan engages directly with the NAD+ and sirtuin frameworks that intersect with the Klotho pathway and is the most accessible research-adjacent book on this territory for a non-specialist reader, available on Amazon. Dave Asprey’s Super Human examines aging biomarker frameworks and lifestyle optimization from a practitioner angle, available on Amazon. For books covering Japanese longevity science and the research background behind findings like the Kuro-o discovery, see available titles on Amazon.

---

Research cluster: Klotho Protein and Aging: What the 1997 Japanese Discovery Actually Shows | Sirtuins, NAD+, and Caloric Restriction | FOXO3 and Okinawan Centenarian Genetics | The Epigenetic Clock and Japanese Longevity | mTOR, Caloric Restriction, and Aging | Cellular Senescence and Senolytics